Amanda Gustafsson

Doktorand vid Institutionen för immunologi, genetik och patologi; Forskningsprogram: Cancerprecisionsmedicin; Forskargrupp Marika Nestor

E-post:: amanda.gustafsson@igp.uu.se
Besöksadress:: Dag Hammarskjölds väg 20
751 85 Uppsala
Postadress:: Rudbecklaboratoriet
751 85 UPPSALA

Ladda ned kontaktuppgifter för Amanda Gustafsson vid Institutionen för immunologi, genetik och patologi; Forskningsprogram: Cancerprecisionsmedicin; Forskargrupp Marika Nestor

Publikationer

Senaste publikationer

[¹⁶¹Tb]Tb-DOTATATE as a potential treatment option for neuroblastoma

Chopra, Saloni; Xu, Tianqi; Berglund, Hanna; Gustafsson, Amanda et al.

Ingår i EJNMMI Research, 2026
- DOI för [¹⁶¹Tb]Tb-DOTATATE as a potential treatment option for neuroblastoma
- Ladda ner fulltext (pdf) av [¹⁶¹Tb]Tb-DOTATATE as a potential treatment option for neuroblastoma
Preclinical Validation of [¹⁷⁷Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials

Mortensen, Anja C. L.; Mohajershojai, Tabassom; Gustafsson, Amanda; Berglund, Hanna et al.

Ingår i Journal of Nuclear Medicine, s. 269-275, 2026
- DOI för Preclinical Validation of [¹⁷⁷Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials
- Ladda ner fulltext (pdf) av Preclinical Validation of [¹⁷⁷Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials

Alla publikationer

Artiklar i tidskrift

[¹⁶¹Tb]Tb-DOTATATE as a potential treatment option for neuroblastoma

Chopra, Saloni; Xu, Tianqi; Berglund, Hanna; Gustafsson, Amanda et al.

Ingår i EJNMMI Research, 2026
- DOI för [¹⁶¹Tb]Tb-DOTATATE as a potential treatment option for neuroblastoma
- Ladda ner fulltext (pdf) av [¹⁶¹Tb]Tb-DOTATATE as a potential treatment option for neuroblastoma
Preclinical Validation of [¹⁷⁷Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials

Mortensen, Anja C. L.; Mohajershojai, Tabassom; Gustafsson, Amanda; Berglund, Hanna et al.

Ingår i Journal of Nuclear Medicine, s. 269-275, 2026
- DOI för Preclinical Validation of [¹⁷⁷Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials
- Ladda ner fulltext (pdf) av Preclinical Validation of [¹⁷⁷Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials